(168) Advanced lentiviral vector engineering with polymer surface modification for CAR-T cell therapy
Introduction: CAR-T cells have revolutionized blood cancer treatment by targeting and eliminating B cells. However, their ex vivo production remains complex and costly. In situ therapies emerged as promising alternatives but face challenges such as off-targeting, immunogenicity and gene delivery efficiency [1-2]. Alaya.bio’s technology combines biodegradable polymers with lentivectors (LVs). Our VSV-G-deficient LVs lack cell transduction ability until coated with pH-responsive cationic polymers, while modification with shielding polymers enhances stability and allows conjugation with targeting agents [3-5].
Learning Objectives:
Show the interplay between high quality but complex LVs and polymers for functional nanoparticles
Document the pros & cons of two LVs coating strategies, layer-by-layer versus self-assembly
Understand how surface modification and zeta potential affect nanoparticle fate in vitro
